Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.

We developed a computational algorithm for evaluating the possibility of cytochrome P450-mediated metabolic transformations that xenobiotics molecules undergo in the human body. First, we compiled a database of known human cytochrome P-450 substrates, products, and nonsubstrates for 38 enzyme-specific groups (total of 2200 compounds). Second, we determined the cytochrome-mediated metabolic reactions most typical for each group and examined the substrates and products of these reactions. To assess the probability of P450 transformations of novel compounds, we built a nonlinear quantitative structure-metabolism relationships (QSMR) model based on Kohonen self-organizing maps (SOM). This neural network QSMR model incorporated a predefined set of physicochemical descriptors encoding the key molecular properties that define the metabolic fate of individual molecules. Isozyme-specific groups of substrate molecules were visualized, thus facilitating prediction of tissue-specific metabolism. The developed algorithm can be used in early stages of drug discovery as an efficient tool for the assessment of human metabolism and toxicity of novel compounds in designing discovery libraries and in lead optimization.

[1]  Konstantin V. Balakin,et al.  Property-Based Design of GPCR-Targeted Library , 2002, J. Chem. Inf. Comput. Sci..

[2]  M. Kietzmann Conjugation Reactions in Drug Metabolism: Mulder, G.J. (Ed.), X+413 pp., London, New York, Philadelphia: Taylor and Francis (1990) , 1991 .

[3]  P. Shields,et al.  Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. , 1995, Pharmacogenetics.

[4]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[5]  F. Gonzalez,et al.  Human cytochromes P450: evolution and cDNA-directed expression. , 1992, Environmental health perspectives.

[6]  L. Koymans,et al.  Cytochromes P450: their active-site structure and mechanism of oxidation. , 1993, Drug metabolism reviews.

[7]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[8]  N Bodor Retrometabolic approaches for drug design and targeting. , 1997, Die Pharmazie.

[9]  R. Cattell,et al.  A Comprehensive Trial Of The Scree And Kg Criteria For Determining The Number Of Factors. , 1977, Multivariate behavioral research.

[10]  L. Hederstedt,et al.  Molecular biology of cytochromes , 1992 .

[11]  I. Jolliffe Principal Component Analysis , 2002 .

[12]  Sergei V. Trepalin,et al.  SLIPPER-2001 - Software for Predicting Molecular Properties on the Basis of Physicochemical Descriptors and Structural Similarity , 2002, J. Chem. Inf. Comput. Sci..

[13]  D. Nebert Multiple forms of inducible drug-metabolizing enzymes: A reasonable mechanism by which any organism can cope with adversity , 1979, Molecular and Cellular Biochemistry.

[14]  Jens Sadowski,et al.  The Use of Self-organizing Neural Networks in Drug Design , 2002 .

[15]  N. Vermeulen,et al.  A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.

[16]  F. Darvas,et al.  Predicting metabolic pathways by logic programming , 1988 .

[17]  R. Remmel,et al.  Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development. , 2002 .

[18]  F. Gonzalez,et al.  Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.

[19]  Andreas Zell,et al.  Locating Biologically Active Compounds in Medium-Sized Heterogeneous Datasets by Topological Autocorrelation Vectors: Dopamine and Benzodiazepine Agonists , 1996, J. Chem. Inf. Comput. Sci..

[20]  F. Darvas,et al.  Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries. , 2000 .

[21]  Ferenc Darvas,et al.  Metabolexpert: An Expert System for Predicting Metabolism of Substances , 1987 .

[22]  K. Korzekwa,et al.  An assessment of the reaction energetics for cytochrome P450-mediated reactions. , 2001, Archives of biochemistry and biophysics.

[23]  C. Ioannides Cytochromes P450 Metabolic and Toxicological Aspects , 1996 .

[24]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[25]  R. Cattell The Scree Test For The Number Of Factors. , 1966, Multivariate behavioral research.

[26]  K. Kawajiri,et al.  Genetic Polymorphisms in the 5 '-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P 45011 E 1 Gene ' , 2008 .

[27]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[28]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  A. D. Rodrigues,et al.  Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.

[30]  Bernd Beck,et al.  Descriptors, physical properties, and drug-likeness. , 2002, Journal of medicinal chemistry.

[31]  P. Erhardt,et al.  Microsomal O-demethylation, N-demethylation and aromatic hydroxylation in the presence of bisulfite and dithiothreitol. , 1975, Research communications in chemical pathology and pharmacology.

[32]  Johann Gasteiger,et al.  The comparison of geometric and electronic properties of molecular surfaces by neural networks: Application to the analysis of corticosteroid-binding globulin activity of steroids , 1996, J. Comput. Aided Mol. Des..

[33]  F. Gonzalez,et al.  The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.

[34]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[35]  Gilles Klopman,et al.  META. 1. A Program for the Evaluation of Metabolic Transformation of Chemicals , 1994, J. Chem. Inf. Comput. Sci..

[36]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[37]  L. Guttman Some necessary conditions for common-factor analysis , 1954 .

[38]  O. Stiffelman,et al.  Computer modeling of 3D structures of cytochrome P450s. , 1996, Biochimie.

[39]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.